Get the Stockscreener App
6.84
3.25%
-0.23
After Hours:
6.82
-0.02
-0.29%
Solid Biosciences Inc stock is traded at $6.84, with a volume of 1.26M.
It is down -3.25% in the last 24 hours and up +40.45% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$7.07
Open:
$7.03
24h Volume:
1.26M
Relative Volume:
0.73
Market Cap:
$530.21M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-2.25
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
+2.40%
1M Performance:
+40.45%
6M Performance:
+115.09%
1Y Performance:
-23.32%
1-Day Range:
$6.75
$7.16
1-Week Range:
$6.47
$7.37
52-Week Range:
$2.41
$10.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.84 | 548.03M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
What are the latest earnings results for Solid Biosciences Inc.Daily Trading Outlook With Proven Results - jammulinksnews.com
Institutional Tools Highlight Unusual Flow in Solid Biosciences Inc.Optimized Watchlist With Daily Adjustments Launched - metal.it
What institutions are buying Solid Biosciences Inc. stock nowEarnings Play Trade Plan With Alerts Shared - metal.it
Technical Charts Suggest Momentum Shift in Solid Biosciences Inc.Oversold Recovery Opportunity Stocks Attract Buyers - metal.it
Solid Biosciences Inc. Approaches Support With Recovery in SightEntry Alert Based on Volume Spikes Detected - metal.it
Solid Biosciences’ SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com
What catalysts could drive Solid Biosciences Inc. stock higher in 2025Entry Signal Tracker For Consistent Profits - jammulinksnews.com
What makes Solid Biosciences Inc. stock price move sharplySmart Portfolio Recommendation For Beginners - jammulinksnews.com
What is the dividend policy of Solid Biosciences Inc. stockAchieve rapid portfolio growth with smart picks - jammulinksnews.com
Momentum Traders Eye Solid Biosciences Inc. for Quick BounceROI Boosting Trade Opportunity Calendar Published - metal.it
Should I hold or sell Solid Biosciences Inc. stock in 2025Access powerful market insights for free - jammulinksnews.com
Why Solid Biosciences Inc. stock attracts strong analyst attention2x Return Forecast - metal.it
How volatile is Solid Biosciences Inc. stock compared to the marketMarket-leading profit generation - jammulinksnews.com
Will Solid Biosciences Inc. stock benefit from interest rate changesFree Predictions - metal.it
J.P. Morgan Keeps Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
What drives Solid Biosciences Inc. stock priceTriple-digit wealth increases - Autocar Professional
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $15 - 富途牛牛
Is Solid Biosciences Inc. a good long term investmentUnstoppable profit momentum - PrintWeekIndia
Solid Biosciences Inc. Stock Analysis and ForecastExplosive capital gains - Autocar Professional
What analysts say about Solid Biosciences Inc. stockFree Popular Stock Recommendations - PrintWeekIndia
Solid Biosciences Receives FDA Fast Track Designation for - GlobeNewswire
Solid Biosciences and the Breakthrough Potential of SGT-501 for CPVT: A Rare Disease Play with Explosive Upside - AInvest
Solid Bio gets FDA fast track status for heart disease drug - Seeking Alpha
Solid Bio Green on Fast Track Nod - Baystreet.ca
Solid Biosciences receives FDA Fast Track designation for CPVT therapy By Investing.com - Investing.com Canada
Solid Biosciences receives FDA Fast Track designation for CPVT therapy - Investing.com Australia
Breakthrough CPVT Gene Therapy Receives Triple FDA Designations, Phase 1b Trial Set for Q4 2025 - Stock Titan
Cantor Fitzgerald Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):